Page 1328 - Williams Hematology ( PDFDrive )

1302 Part X: Malignant Myeloid Diseases Chapter 84: Polycythemia Vera 1303

83. Anger BR, Seifried E, Scheppach J, et al: Budd-Chiari syndrome and thrombosis of 116. Gilbert HS, Warner RR, Wasserman LR: A study of histamine in myeloproliferative
other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr disease. Blood 28(6):795–806, 1966.
67(16):818–825, 1989. 117. Falanga A, Marchetti M, Evangelista V, et al: Polymorphonuclear leukocyte activation
84. De Stefano V, Fiorini A, Rossi E, et al: Incidence of the JAK2 V617F mutation among and hemostasis in patients with essential thrombocythemia and polycythemia vera.
patients with splanchnic or cerebral venous thrombosis and without overt chronic mye- Blood 96(13):4261–4266, 2000.
loproliferative disorders. J Thromb Haemost 5(4):708–714, 2007. 118. Vannucchi AM: Insights into the pathogenesis and management of thrombosis in poly-
85. De Stefano V, Teofili L, Leone G, et al: Spontaneous erythroid colony formation as the cythemia vera and essential thrombocythemia. Intern Emerg Med 5(3):177–184, 2010.
clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syn- 119. Cerutti A, Custodi P, Duranti M, et al: Thrombopoietin levels in patients with primary
drome or portal vein thrombosis. Semin Thromb Hemost 23(5):411–418, 1997. and reactive thrombocytosis. Br J Haematol 99(2):281–284, 1997.
86. Colaizzo D, Amitrano L, Tiscia GL, et al: The JAK2 V617F mutation frequently occurs 120. Shih LY, Lee CT: Identification of masked polycythemia vera from patients with idio-
in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5(1):55– pathic marked thrombocytosis by endogenous erythroid colony assay. Blood 83(3):744–
61, 2007. 748, 1994.
87. Reikvam H, Tiu RV: Venous thromboembolism in patients with essential thrombo- 121. Yamamoto K, Sekiguchi E, Takatani O: Abnormalities of epinephrine-induced platelet
cythemia and polycythemia vera. Leukemia 26(4):563–571, 2012. aggregation and adenine nucleotides in myeloproliferative disorders. Thromb Haemost
88. Srinivasan P, Rela M, Prachalias A, et al: Liver transplantation for Budd-Chiari syn- 52(3):292–296, 1984.
drome. Transplantation 73(6):973–977, 2002. 122. Mehta P, Mehta J, Ross M, et al: Decreased platelet aggregation but increased throm-
89. Valla D, Casadevall N, Lacombe C, et al: Primary myeloproliferative disorder and boxane A2 generation in polycythemia vera. Arch Intern Med 145(7):1225–1227, 1985.
hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 123. Landolfi R, Ciabattoni G, Patrignani P, et al: Increased thromboxane biosynthesis in
20 patients with Budd-Chiari syndrome. Ann Intern Med 103(3):329–334, 1985. patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation
90. Murphy S: Polycythemia vera. Dis Mon 38(3):153–212, 1992. in vivo. Blood 80(8):1965–1971, 1992.
91. Siegel FP, Tauscher J, Petrides PE: Aquagenic pruritus in polycythemia vera: Charac- 124. Berild D, Hasselbalch H, Knudsen JB: Platelet survival, platelet factor-4 and bleeding
teristics and influence on quality of life in 441 patients. Am J Hematol 88(8):665–669, time in myeloproliferative disorders. Scand J Clin Lab Invest 47(5):497–501, 1987.
2013. 125. Kutti J, Weinfeld A: Platelet survival in active polycythaemia vera with reference to the
92. Jackson N, Burt D, Crocker J, et al: Skin mast cells in polycythaemia vera: Relationship haematocrit level. An experimental study before and after phlebotomy. Scand J Haema-
to the pathogenesis and treatment of pruritus. Br J Dermatol 116(1):21–29, 1987. tol 8(5):405–414, 1971.
93. Steinman HK, Kobza-Black A, Lotti TM, et al: Polycythaemia rubra vera and water- 126. Le Blanc K, Lindahl T, Rosendahl K, et al: Impaired platelet binding of fibrinogen due to
induced pruritus: Blood histamine levels and cutaneous fibrinolytic activity before and a lower number of GPIIB/IIIA receptors in polycythemia vera. Thromb Res 91(6):287–
after water challenge. Br J Dermatol 116(3):329–333, 1987. 295, 1998.
94. Buchanan JG, Ameratunga RV, Hawkins RC: Polycythemia vera and water-induced 127. Afshar-Kharghan V, Lopez JA, Gray LA, et al: Hemostatic gene polymorphisms and the
pruritus: Evidence against mast cell involvement. Pathology 26(1):43–45, 1994. prevalence of thrombotic complications in polycythemia vera and essential thrombo-
95. Cox NH, Leggat H: Sweet’s syndrome associated with polycythemia rubra vera. J Am cythemia. Blood Coagul Fibrinolysis 15(1):21–24, 2004.
Acad Dermatol 23(6 Pt 1):1171–1172, 1990. 128. Landolfi R, Cipriani MC, Novarese L: Thrombosis and bleeding in polycythemia vera
96. Furukawa T, Takahashi M, Shimada H, et al: Polycythaemia vera with Sweet’s and essential thrombocythemia: Pathogenetic mechanisms and prevention. Best Pract
syndrome. Clin Lab Haematol 11(1):67–70, 1989. Res Clin Haematol 19(3):617–633, 2006.
97. Davis MD, O’Fallon WM, Rogers RS, 3rd, et al: Natural history of erythromelalgia: 129. Binder RA, Gilbert HS: Muramidase in polycythemia vera. Blood 36(2):228–232, 1970.
Presentation and outcome in 168 patients. Arch Dermatol 136(3):330–336, 2000. 130. Gilbert HS, Krauss S, Pasternack B, et al: Serum vitamin B12 content and unsaturated
98. van Genderen PJ, Lucas IS, van Strik R, et al: Erythromelalgia in essential thrombo- vitamin B12-binding capacity in myeloproliferative disease. Value in differential diag-
cythemia is characterized by platelet activation and endothelial cell damage but not by nosis and as indicators of disease activity. Ann Intern Med 71(4):719–729, 1969.
thrombin generation. Thromb Haemost 76(3):333–338, 1996. 131. Moliterno AR, Williams DM, Rogers O, et al: Molecular mimicry in the chronic myelo-
99. van Genderen PJ, Michiels JJ: Erythromelalgia: A pathognomonic microvascular proliferative disorders: Reciprocity between quantitative JAK2 V617F and Mpl expres-
thrombotic complication in essential thrombocythemia and polycythemia vera. Semin sion. Blood 108(12):3913–3915, 2006.
Thromb Hemost 23(4):357–363, 1997. 132. Antonioli E, Guglielmelli P, Poli G, et al: Influence of JAK2V617F allele burden on phe-
100. Wanless IR, Peterson P, Das A, et al: Hepatic vascular disease and portal hypertension notype in essential thrombocythemia. Haematologica 93(1):41–48, 2008.
in polycythemia vera and agnogenic myeloid metaplasia: A clinicopathological study of 133. Wang L, Swierczek SI, Lanikova L, et al: The relationship of JAK2(V617F) and acquired
145 patients examined at autopsy. Hepatology 12(5):1166–1174, 1990. UPD at chromosome 9p in polycythemia vera. Leukemia 28(4):938–941, 2014.
101. Tinney WS, Hall BE, Giffin HZ: Polycythemia vera and peptic ulcer. Mayo Clin Proc 134. Lippert E, Girodon F, Hammond E, et al: Concordance of assays designed for the quan-
18:24, 1943. tification of JAK2V617F: A multicenter study. Haematologica 94(1):38–45, 2009.
102. Dingli D, Utz JP, Krowka MJ, et al: Unexplained pulmonary hypertension in chronic 135. Ma W, Kantarjian H, Zhang X, et al: Higher detection rate of JAK2 mutation using
myeloproliferative disorders. Chest 120(3):801–808, 2001. plasma. Blood 111(7):3906–3907, 2008.
103. Garcia-Manero G, Schuster SJ, Patrick H, et al: Pulmonary hypertension in patients 136. Ma W, Kantarjian H, Verstovsek S, et al: Hemizygous/homozygous and heterozygous
with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 60(2):130– JAK2 mutation detected in plasma of patients with myeloproliferative diseases: Cor-
135, 1999. relation with clinical behaviour. Br J Haematol 134(3):341–343, 2006.
104. Newton LK: Neurologic complications of polycythemia and their impact on therapy. 137. Salama ME, Swierczek SI, Hickman K, et al: Plasma quantitation of JAK2 mutation is
Oncology (Williston Park) 4(3):59–64; discussion 64–66, 1990. not suitable as a clinical test: An artifact of storage. Blood 114(1):223–224; author reply
105. Jackson A, Burton IE: Retroperitoneal mass and spinal cord compression due to 224, 2009.
extramedullary haemopoiesis in polycythaemia rubra vera. Br J Radiol 62(742):944– 138. Jones AV, Cross NC, White HE, et al: Rapid identification of JAK2 exon 12 mutations
947, 1989. using high resolution melting analysis. Haematologica 93(10):1560–1564, 2008.
106. Wasserman LR, Gilbert HS: Surgical bleeding in polycythemia vera. Ann N Y Acad Sci 139. Percy MJ, Scott LM, Erber WN, et al: The frequency of JAK2 exon 12 mutations in
115:122–138, 1964. idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica
107. Gilbert HS: Modern treatment strategies in polycythemia vera. Semin Hematol 40(1 92(12):1607–1614, 2007.
Suppl 1):26–29, 2003. 140. Pietra D, Li S, Brisci A, et al: Somatic mutations of JAK2 exon 12 in patients with JAK2
108. Thiele J, Kvasnicka HM: Diagnostic impact of bone marrow histopathology in poly- (V617F)-negative myeloproliferative disorders. Blood 111(3):1686–1689, 2008.
cythemia vera (PV). Histol Histopathol 20(1):317–328, 2005. 141. Rapado I, Grande S, Albizua E, et al: High resolution melting analysis for JAK2 Exon
109. Finazzi G, Caruso V, Marchioli R, et al: Acute leukemia in polycythemia vera: An anal- 14 and Exon 12 mutations: A diagnostic tool for myeloproliferative neoplasms. J Mol
ysis of 1638 patients enrolled in a prospective observational study. Blood 105(7):2664– Diagn 11(2):155–161, 2009.
2670, 2005. 142. Schnittger S, Bacher U, Haferlach C, et al: Detection of JAK2 exon 12 mutations in 15
110. Cassinat B, Laguillier C, Gardin C, et al: Classification of myeloproliferative disorders patients with JAK2V617F negative polycythemia vera. Haematologica 94(3):414–418,
in the JAK2 era: Is there a role for red cell mass? Leukemia 22(2):452–453, 2008. 2009.
111. Johansson PL, Safai-Kutti S, Kutti J: An elevated venous haemoglobin concentration 143. Birgegard G, Wide L: Serum erythropoietin in the diagnosis of polycythaemia and after
cannot be used as a surrogate marker for absolute erythrocytosis: A study of patients phlebotomy treatment. Br J Haematol 81(4):603–606, 1992.
with polycythaemia vera and apparent polycythaemia. Br J Haematol 129(5):701–705, 144. Messinezy M, Westwood NB, El-Hemaidi I, et al: Serum erythropoietin values in ery-
2005. throcytoses and in primary thrombocythaemia. Br J Haematol 117(1):47–53, 2002.
112. Barbui T, Thiele J, Gisslinger H, et al: Masked polycythemia vera (mPV): Results of an 145. Mossuz P, Girodon F, Donnard M, et al: Diagnostic value of serum erythropoietin level
international study. Am J Hematol 89(1):52–54, 2014. in patients with absolute erythrocytosis. Haematologica 89(10):1194–1198, 2004.
113. Spivak JL: Diagnosis of the myeloproliferative disorders: Resolving phenotypic mim- 146. Remacha AF, Montserrat I, Santamaria A, et al: Serum erythropoietin in the diagnosis
icry. Semin Hematol 40(1 Suppl 1):1–5, 2003. of polycythemia vera. A follow-up study. Haematologica 82(4):406–410, 1997.
114. Beutler E: Polycythemia. Med Grand Rounds 3:142, 1984. 147. Prchal JT: Classification and molecular biology of polycythemias (erythrocytoses) and
115. Spivak JL, Silver RT: The revised World Health Organization diagnostic criteria for thrombocytosis. Hematol Oncol Clin North Am 17(5):1151–1158, vi, 2003.
polycythemia vera, essential thrombocytosis, and primary myelofibrosis: An alternative 148. Weinberg RS: In vitro erythropoiesis in polycythemia vera and other myeloproliferative
proposal. Blood 112(2):231–239, 2008. disorders. Semin Hematol 34(1):64–69, 1997.

Kaushansky_chapter 84_p1291-1306.indd 1303 9/21/15 11:11 AM